Peptides for IBS and Leaky Gut: What the Research Shows

Key Takeaways

• Compounds covered: BPC-157, larazotide acetate (AT-1001), KPV (Lys-Pro-Val)
• Goal area: Intestinal permeability, mucosal healing, and gut inflammation in IBS-adjacent conditions
• Evidence range: Phase 3 RCT in humans (larazotide, celiac disease), animal studies (BPC-157), in vitro/murine models (KPV)
• Regulatory range: Larazotide is investigational (Phase 3 complete, not approved); BPC-157 is on FDA's Category 2 bulk drug substance list — the category for substances FDA has identified as presenting significant safety risks when compounded — and is subject to an April 2026 FDA removal action with PCAC review pending; KPV fails all three § 353a(b)(1)(A) bulk substance criteria and is subject to the same FDA Category 2 removal action with PCAC review pending
• Key biomarkers for IBS/leaky gut: hs-CRP, fecal calprotectin, zonulin, FABP2, comprehensive metabolic panel, CBC
• As of April 2026: No peptide discussed here is FDA-approved for IBS or intestinal permeability. BPC-157 compounding is restricted. "Leaky gut" is not a recognized clinical diagnosis.
• Bottom line: Larazotide has the strongest human evidence for gut barrier restoration. BPC-157 has the broadest preclinical mucosal repair dataset. KPV targets the inflammatory pathway specifically. No compound has FDA approval for these indications.

Understanding Intestinal Permeability and IBS: The Biology

IBS (irritable bowel syndrome) is defined by recurring abdominal pain and altered bowel habits without structural abnormality — a functional diagnosis. Increased intestinal permeability, by contrast, is a measurable structural phenomenon: the disruption of tight junction proteins that maintain the epithelial barrier separating the gut lumen from systemic circulation. These two conditions overlap but are not the same thing, and not all IBS patients have demonstrable permeability changes.

Fasano's landmark 2011 review in Physiological Reviews established zonulin as the regulator of intestinal barrier function and characterized its role as a biological gateway to inflammation and autoimmunity — placing intestinal permeability on a firm molecular footing. His 2020 review in F1000Research updated the field, linking zonulin-mediated permeability to chronic inflammatory diseases. However, Massier and colleagues, in a 2021 critical appraisal in Gut, provided important limitations on zonulin as a biomarker, noting measurement variability and the ongoing scientific debate about "leaky gut" as a clinical diagnosis. This nuance matters: intestinal permeability is real and measurable; its clinical significance varies by context and population.

Macura and colleagues, in a 2024 review in Clinical and Experimental Medicine, reviewed causes, diseases, and therapy options for intestinal permeability disturbances — providing the contemporary clinical landscape for the article's scope.

Three mechanisms are relevant to peptide interventions in this space. Tight junction regulation directly prevents paracellular gaps from forming — the mechanism targeted by larazotide. Mucosal cytoprotection and repair addresses structural damage to the epithelial lining after injury — the mechanism for which BPC-157 has the most preclinical evidence. Anti-inflammatory signaling suppresses the cytokine cascades driving mucosal inflammation in IBD and IBS with inflammatory drivers — the mechanism KPV addresses. Each is distinct. Each has different evidence.

The gut-brain axis adds systemic relevance. Sikiric and colleagues, in a 2023 paper in Pharmaceuticals, characterized BPC-157's potential for recovering gut-brain axis function — relevant to IBS, where gut-brain crosstalk is a recognized pathophysiological feature. Stevens and colleagues, in a 2018 paper in Gut, documented correlations between gut permeability biomarkers (zonulin, FABP2) and anxiety and depression symptom scores linked to microbiome alterations, directly implicating barrier dysfunction in the mood co-morbidities common in IBS.

Peptides Studied for IBS and Intestinal Permeability: A Quick Comparison

The following peptides have published evidence relevant to IBS-related mechanisms or intestinal permeability. They are listed by strength of clinical evidence, from most-studied in humans to least.

• Compound: Larazotide acetate. Mechanism for IBS/leaky gut: Promotes tight junction assembly via the zonulin pathway, directly preventing paracellular gaps and reducing measurable intestinal permeability. Evidence: Phase 3 RCTs in celiac disease (2 completed trials); Phase 2 data in non-celiac applications; 2025 publication continuing active investigation. FDA status: Has completed Phase 3 RCTs for celiac disease; remains under investigation. Not FDA-approved. Not available through US compounding pharmacies for general clinical use. SP availability: Not currently available through Superpower. Route: Oral.
• Compound: BPC-157. Mechanism for IBS/leaky gut: Cytoprotective, mucosal-regenerative, and intestinal barrier-stabilizing via VEGFR2 activation, nitric oxide signaling, and structural epithelial repair. Evidence: Extensive animal studies; Phase 2 IBD trial context; gut-brain axis recovery evidence in animal models; no completed Phase 3 RCT. FDA status: Not FDA-approved; FDA Category 2 bulk drug substance — the category for substances FDA has identified as presenting significant safety risks when compounded — subject to an April 2026 FDA removal action with PCAC review pending; compounding under Section 503A is not a lawful pathway. SP availability: Not currently available through Superpower. Route in preclinical studies: Subcutaneous injection or oral (GI-specific effects in animal models). No lawful US human use pathway.
• Compound: KPV. Mechanism for IBS/leaky gut: Suppresses NF-κB and MAP kinase inflammatory cascades in intestinal epithelial cells and macrophages via PepT1-mediated uptake. Evidence: In vitro cell models; murine colitis studies; delivery system research; no human clinical trial. FDA status: Not FDA-approved; not on the FDA 503A Category 1 permitted bulk drug substances list; not a component of any FDA-approved drug; no applicable USP/NF monograph — failing all three § 353a(b)(1)(A) bulk substance criteria; subject to an April 2026 FDA Category 2 removal action with PCAC review pending; not legally available by prescription, through compounding, or for direct sale for human use in the US. SP availability: Not currently available through Superpower. Route: Oral nanoparticle (research); topical mucosal formulations in research.

Compounds listed as research-only have not completed the clinical trial process required for FDA approval. They are not legal to prescribe or sell for human use in the US. Their inclusion here is for educational context only.

Peptides Studied for IBS and Intestinal Permeability: Individual Profiles

Each compound targets a distinct mechanism. Evaluating them separately is what makes any clinical discussion about gut peptides productive.

Larazotide acetate: tight junction restoration with human RCT data

Larazotide acetate (AT-1001) is a synthetic octapeptide that acts on the zonulin pathway to promote tight junction assembly in intestinal epithelial cells. Its mechanism was established in vitro by Gopalakrishnan and colleagues in Peptides in 2012, demonstrating larazotide promotes tight junction assembly in epithelial cells. A companion paper in the same journal by Gopalakrishnan and colleagues confirmed larazotide's tight junction regulatory effects in both in vitro and in vivo models. Slifer, in a 2021 pharmacological review in American Journal of Physiology: Gastrointestinal and Liver Physiology, provided a comprehensive pharmacological review of larazotide covering mechanism, clinical trials, and development status. [Phase 3 RCT]

The pivotal human study is a randomized double-blind placebo-controlled trial by Leffler and colleagues published in the American Journal of Gastroenterology in 2012, in which larazotide acetate reduced celiac disease activation markers and reduced intestinal permeability during gluten challenge in human subjects. Kelly and colleagues published a parallel randomized placebo-controlled study in Alimentary Pharmacology & Therapeutics in 2013 confirming larazotide's clinical efficacy in celiac disease patients undergoing gluten challenge. Khaleghi and colleagues, in a 2016 review in Therapeutic Advances in Gastroenterology, reviewed larazotide's utility in celiac disease and summarized the accumulated evidence base.

Beyond celiac disease, Slifer and colleagues, in a 2021 study in PLoS One, showed larazotide, in an ischemia-injured porcine jejunum model, promoted tight junction repair and mucosal recovery, extending its relevance to acute intestinal injury. Kim and colleagues, in a 2025 paper in Biomedicines, continue to characterize larazotide's protective role on the intestinal mucosal barrier, reflecting ongoing active investigation. Larazotide is the compound most directly relevant to measurable intestinal permeability as a clinical target. It is not FDA-approved but represents the most clinically advanced gut-barrier peptide in this category.

BPC-157: mucosal repair and IBS-adjacent mechanisms

BPC-157's relevance to IBS and intestinal permeability operates through a different mechanism than larazotide: instead of preventing barrier disruption, it promotes repair of mucosal damage that has already occurred. The foundational review by Sikiric and colleagues in Current Pharmaceutical Design in 2011 established BPC-157 as a novel gastrointestinal therapy with documented cytoprotective properties and Phase 2 IBD trial history. Park and colleagues, in a 2020 paper in Current Pharmaceutical Design, demonstrated BPC-157 attenuates NSAID-induced cytotoxicity by stabilizing intestinal permeability in a preclinical model — a direct mechanism for barrier stabilization relevant to drug-induced gut damage, one of the most common causes of intestinal permeability. [Animal study; Phase 2 IBD context; no IBS-specific Phase 3 RCT]

Klicek and colleagues (Sikiric group), in a 2013 paper in Journal of Physiology and Pharmacology, demonstrated BPC-157 attenuates cysteamine-induced colitis in a rodent model — the most direct preclinical evidence for BPC-157 in an inflammatory bowel model. The 2017 paper in World Journal of Gastroenterology by Duzel and colleagues (Sikiric group) provided new evidence on BPC-157's protection against ischemia-reperfusion injury in the gut — a mechanism of potential relevance in contexts where mucosal compromise occurs; human relevance to IBS has not been established in clinical trials. Sikiric and colleagues' 2018 paper in Current Medicinal Chemistry characterized BPC-157 as a cytoprotective mediator recruiting vasculature via VEGFR2. The IBD clinical trial history was documented in Vuksic and colleagues' (Sikiric group) 2007 paper in Surgery Today, reporting ileoileal anastomosis healing in rats and linking to the IBD trial history — indicating BPC-157 had been evaluated in an earlier IBD clinical context prior to its current FDA Category 2 status.

For IBS specifically — a functional condition without structural pathology in most cases — BPC-157's tissue-repair mechanism is most relevant to the subset of IBS patients with demonstrable mucosal changes, such as post-infectious IBS or IBS with elevated calprotectin. BPC-157 is on FDA's Category 2 bulk drug substance list and, as of April 2026, is subject to an FDA removal action pending PCAC review; compounding under Section 503A is not a lawful pathway. It is not FDA-approved for IBS, intestinal permeability, or any indication, and is not available through Superpower.

KPV: anti-inflammatory signaling for IBD-adjacent gut inflammation

KPV's relevance to IBS and intestinal permeability is primarily through the inflammatory pathway. Dalmasso and colleagues' 2008 paper in Gastroenterology established that KPV reduces intestinal inflammation via PepT1-mediated cellular entry and NF-κB suppression — a mechanism directly relevant to the inflammatory component of IBD and some IBS subtypes. [In vitro; murine colitis model]

Viennois and colleagues, in a 2016 paper in Cellular and Molecular Gastroenterology and Hepatology, characterized KPV's PepT1-mediated activity in a murine colitis-associated cancer model — an important finding for IBD patients concerned about long-term mucosal damage. Xiao and colleagues, in a 2017 paper in Molecular Therapy, showed HA-nanoparticle-delivered KPV reduced ulcerative colitis disease activity scores in murine models — the most direct evidence for KPV in an IBD model. The barrier connection is also established: Fasano and Shea-Donohue's 2012 paper in Nature Reviews Gastroenterology and Hepatology established intestinal permeability regulation by zonulin as having diagnostic and therapeutic implications, providing the broader disease context in which KPV's anti-inflammatory activity matters.

KPV is a research compound. No human clinical trial has been published for any indication. It is not available through licensed prescribers and is not available through Superpower.

Regulatory Status at a Glance

As of April 2026:

• Larazotide acetate: Has completed Phase 3 RCTs for celiac disease; remains under investigation. Not FDA-approved. Not available through US compounding pharmacies for general clinical use.
• BPC-157: Not FDA-approved for any indication. On FDA's Category 2 bulk drug substance list; subject to an April 2026 FDA removal action with PCAC review pending; compounding under Section 503A is not a lawful pathway. Not available through Superpower.
• KPV: Not FDA-approved for any indication. Not on the FDA 503A Category 1 permitted bulk drug substances list, not a component of any FDA-approved drug, and no applicable USP/NF monograph — failing all three statutory criteria under 21 U.S.C. § 353a for lawful 503A bulk compounding. Subject to an April 2026 FDA Category 2 removal action with PCAC review pending. Not legally available by prescription, through compounding, or for direct sale for human use in the US. Not prescribed, compounded, or dispensed through Superpower.

Compounds listed as research-only are not legal to prescribe, compound, or sell for human use in the US. Their presence in this article is for educational context only.

Considerations When Comparing Peptides for IBS and Intestinal Permeability

A provider evaluating gut-targeted peptides for IBS or intestinal permeability will distinguish between the clinical diagnosis question, the mechanism question, and the access question — because they converge differently for each compound in this article.

Direct comparison between these compounds is not straightforward — they have been studied in different populations, at different doses, and using different endpoints. Inferring relative effectiveness from separate trials carries significant methodological limitations.

Confirming what is actually driving your symptoms: IBS is heterogeneous. A subset of patients have demonstrable intestinal permeability changes; others do not. Measurable biomarker data — calprotectin, zonulin, hs-CRP — helps a clinician distinguish IBS presentations with a barrier-dysfunction component from those without, context relevant to evaluating any barrier-targeting compound.

Structural repair vs. inflammatory suppression vs. barrier integrity: These three mechanisms are distinct. BPC-157 addresses structural mucosal repair. KPV addresses inflammatory signaling. Larazotide addresses tight junction assembly. If a provider is evaluating these compounds, the specific driver of symptoms is what determines which mechanism is most clinically relevant.

Evidence level: Larazotide is the only compound here with Phase 3 human RCT data in a gut permeability-driven condition. BPC-157 has extensive preclinical data but no IBS-specific Phase 3 trial. KPV has no human clinical data. This gradient is important context for any conversation with a provider about evidence-based options.

Regulatory status and access: BPC-157 is on FDA's Category 2 bulk drug substance list and is subject to an April 2026 FDA removal action pending PCAC review. Larazotide is investigational. KPV fails all three § 353a bulk substance criteria and is subject to the same FDA Category 2 removal action pending PCAC review. None can be obtained through standard prescribing channels under the current regulatory framework. Access through clinical trial enrollment is the appropriate pathway for compounds at this stage.

This is not an exhaustive list of clinical considerations. A licensed provider — ideally a gastroenterologist — will evaluate your complete clinical picture before discussing any investigational compound.

Safety Considerations

Safety profiles across these compounds are very different. No blanket statement applies.

Larazotide has documented human tolerability from Phase 3 RCTs — the most robust safety foundation of any compound here. BPC-157 has a clean preclinical safety record across extensive animal studies but limited systematic human data. KPV has no Phase 1 human safety data. For any injectable compound, baseline liver and kidney function are standard safety markers. A history of GI malignancy or immunosuppressive therapy requires provider evaluation before any anti-inflammatory peptide is considered. Kharrazian and colleagues, in a 2023 paper in International Journal of Molecular Sciences, characterized associations between intestinal permeability and autoimmune disease antibodies — context relevant when evaluating patients with co-morbid autoimmune conditions where immunosuppression already complicates the safety picture.

Broad contraindications relevant to gut health peptide therapy include:

• Active malignancy involving the GI tract — cytoprotective and angiogenic compounds require provider risk assessment in oncology contexts
• Severe immunosuppression — anti-inflammatory compounds carry theoretical considerations for immune surveillance in immunocompromised individuals
• Pregnancy or breastfeeding — no reproductive safety data exists for any investigational compound in this article
• Known hypersensitivity to any component of a formulation
• Unregulated online sources — products sold outside licensed pharmacy channels cannot be verified for purity, potency, or identity

For compound-specific safety profiles, see the individual compound pages linked above.

What to Test Before Starting Peptides for IBS or Intestinal Permeability

Regardless of which compound you and your provider discuss, baseline biomarker testing establishes a measurable starting point. Without it, there is no objective way to assess whether any intervention is producing expected physiological changes.

• hs-CRP: Quantifies systemic inflammatory burden. Gut barrier disruption elevates systemic CRP through inflammatory cytokine translocation. Baseline hs-CRP characterizes whether gut-driven systemic inflammation is present and provides a reference for tracking any future intervention.
• Fecal calprotectin (provider-ordered): The most sensitive available marker of mucosal gut inflammation — more specific than serum CRP for GI-origin inflammation. Elevated calprotectin distinguishes IBS with mucosal inflammation (relevant to BPC-157, KPV) from purely functional IBS. This test requires a provider order.
• Zonulin (specialty labs): Directly measures tight junction permeability — the primary mechanistic target of larazotide. Elevated serum or stool zonulin provides objective evidence of barrier disruption. Massier and colleagues' 2021 critical appraisal noted zonulin measurement limitations, so interpretation requires clinical context.
• FABP2 (intestinal fatty acid binding protein): Reflects active intestinal epithelial cell damage. Hoshiko and colleagues, in a 2021 study in Healthcare (Basel), documented associations between FABP2 levels and metabolic health markers in healthy adults — one line of evidence supporting FABP2's utility as an intestinal permeability biomarker.
• Comprehensive metabolic panel (ALT, AST, eGFR) via liver health panel: Standard safety baseline for any injectable compound. Liver and kidney function affect pharmacokinetics and establish safety context.
• CBC: Hematologic picture a clinician interprets alongside other markers. Eosinophilia and anemia patterns can be clinically relevant in gut inflammatory presentations.
• Fasting glucose and metabolic markers: GI dysfunction and the gut microbiome affect metabolic markers through multiple pathways. A metabolic baseline contextualizes the full systemic picture.

The gut health biomarker guide covers the full relevant marker set for assessing intestinal health in detail. Establishing this baseline before any intervention is what makes subsequent changes interpretable.

How to Access These Peptides Safely

None of the investigational compounds in this article are available through standard prescribing channels under the current US regulatory framework. Larazotide is investigational and not available through compounding for general use. BPC-157 is on FDA's Category 2 bulk drug substance list and is subject to an April 2026 FDA removal action pending PCAC review; compounding under Section 503A is not a lawful pathway. KPV fails all three § 353a bulk substance criteria and is subject to the same FDA removal action pending PCAC review.

The appropriate pathway for any individual interested in these compounds begins with a gastroenterologist evaluation, standard diagnostic workup for IBS and gut barrier status, and discussion of evidence-based currently available options. Clinical trial enrollment through ClinicalTrials.gov is the appropriate route for anyone seeking access to investigational compounds — it provides the compound, monitoring, and safety oversight that unregulated access cannot.

Products sold online as BPC-157, KPV, or "gut healing peptides" operate outside FDA oversight. Contamination, incorrect dosing, and misidentified compounds are documented risks with unregulated injectable products. Superpower does not facilitate access to research-only or FDA Category 2 compounds.

Understanding Your Baseline

IBS and increased intestinal permeability are conditions where objective measurement matters more than symptom-based trial-and-error. Calprotectin, zonulin, hs-CRP, and FABP2 provide a picture of what is happening at the mucosal level — information that transforms the conversation from "my gut feels bad" to "here is my inflammatory marker, here is my barrier integrity marker, and here is what mechanism is most likely to be relevant." That is the conversation a baseline panel enables.

That principle — establish the objective picture before acting on it — is central to Superpower's approach to preventive health. Whether the discussion with your provider leads to an FDA-approved medication, dietary intervention, clinical trial enrollment, or watchful waiting, the starting point is the same: knowing where your biomarkers stand.

IMPORTANT SAFETY INFORMATION

BPC-157 is not approved by the FDA for any medical use. It is on FDA's Category 2 bulk drug substance list (substances that present significant safety risks when compounded). In April 2026, FDA initiated a removal action with respect to BPC-157; the Pharmacy Compounding Advisory Committee (PCAC) is reviewing its status. Compounding under Section 503A is not a lawful pathway for BPC-157. Research on BPC-157 has been limited primarily to laboratory and animal studies for IBS and intestinal permeability indications. Safety and efficacy for IBS or intestinal permeability have not been established through adequate and well-controlled clinical trials. BPC-157 is not prescribed, compounded, or dispensed through Superpower.

KPV (Lys-Pro-Val) is not approved by the FDA for any medical use. It is not on the FDA 503A Category 1 permitted bulk drug substances list, is not a component of any FDA-approved drug, and has no applicable USP/NF monograph — it therefore fails all three statutory criteria for lawful 503A bulk compounding under 21 U.S.C. § 353a. As of April 2026, KPV is subject to an FDA Category 2 removal action pending PCAC review. Research on KPV has been limited to in vitro cell models and murine animal studies. Its safety, efficacy, appropriate dosing, and long-term effects in humans have not been established. KPV is not legally available by prescription, through compounding, or for direct sale for human use in the US. KPV is not prescribed, compounded, or dispensed through Superpower.

Larazotide acetate is an investigational peptide that has completed Phase 3 clinical trials for celiac disease; it remains under investigation and is not currently FDA-approved for IBS, intestinal permeability, or any indication. Larazotide is not currently available through US compounding pharmacies for general clinical use. Larazotide is not prescribed or dispensed through Superpower.

This article uses the scientifically appropriate term "increased intestinal permeability" rather than "leaky gut," which is not a recognized medical diagnosis. Individuals with symptoms of IBS or suspected intestinal permeability should seek evaluation by a licensed gastroenterologist before considering any investigational compound.

All injectable peptide therapies require a prescription from a licensed healthcare provider. This content is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide compound. Individual health history, GI diagnoses, current medications, and baseline lab values affect both eligibility and response.

Full FDA-approved prescribing information at dailymed.nlm.nih.gov.